The Erythropoietin in Methanol Associated Optic Neuropathy (EPO-MAON) trial (ClinicalTrials.gov Identifier: NCT02376881) is designed as a randomized, controlled trial to assess the efficacy of 20,000 IU EPO IV infusion for three successive days in improvement of visual outcome after three months following the treatment. This evidence concerns the gene EPO and optic nerve disorder.